New York, USA – December 9, 2020 – Neutralizing antibodies are imperative for the researches on various targets. Quite a ratio of the recent breakthroughs in novel therapies is related to the neutralizing antibodies, especially the research on the currently pandemic COVID-19, indicating that the neutralizing antibodies obtained from the cured patients have therapeutic effects. Creative Biolabs, based upon years of experience in antibody production and engineering, provides high-standard antibody products that are developed from the exclusive platform for neutralizing antibody production, and is extending the scope of capability, aiming to cover as many research areas as possible.
The neutralizing antibodies at Creative Biolabs are classified into three categories according to different properties and purposes of use, which are primary antibody, second antibody, and isotype control.
* A primary antibody is optimal for the detection of protein expression, location, modification, and function, which directly binds to the antigen of research interest.
* Secondary antibodies, used for signal detection and amplification, can bind to the antigen of interest directly, which are usually labeled with fluorescent dyes (e.g. FITC, PE) or enzymes (e.g. HRP, AP).
* Isotype control is not specific to the target but matches the primary antibody isotype and is mainly used as a negative control to help differentiate designated antibody signals from background signals caused by off-targeting binding. Featured products are Human IgG1/IgG2/IgG4 Isotype Control, Mouse IgG2a/IgG2b Isotype Control, Rat IgG2a/IgG2b Isotype Control, etc.
The application scope of neutralizing antibodies provided by Creative Biolabs is broad, covering cellular marker, stem cell, cancer research, and the SARS-CoV-2, and applies to various lab tests, such as enzyme-linked immunosorbent assay (ELISA), flow cytometry (FC), and western blot (WB). In addition, criteria of neutralizing antibody assay can help researchers screen out desired antibodies instantly, including protein-based assay (ELISA antibodies, WB antibodies, IP antibodies, etc.), cell-based assay (FC, ICFC, IHC, etc.), tissue-based assay, and functional assay.
As the technologies are evolving accompanied by enormous breakthroughs, Creative Biolabs is extending the scope of capability and will do the best to accommodate clients’ challenging projects as they can with optimal antibody products. More details regarding the products and solutions are available at https://neutab.creative-biolabs.com.
About the Company
Creative Biolabs is a life-science company that was established in New York in 2004 by a group of ambitious scientists who are specialized in antibody production and engineering. During over 10 years of exploration, Creative Biolabs has accomplished dozens of successful cases from worldwide customers and accumulated rich experience, becoming more and more professional in the antibody discovery for novel therapies and well recognized in the industry.